Jerome H. Goldschmidt

Author

Also Known As

J Goldschmidt, J. GOLDSCHMIDT, J. Goldschmidt, J. H. Goldschmidt, Jerome Goldschmidt, Jerome H Goldschmidt, Jerome H. Goldschmidt

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Mountain Blue Cancer Care Center Sarah Cannon Florida Cancer Specialists & Research Institute Willamette Valley Cancer Institute and Research Center Texas Oncology

About

Jerome H. Goldschmidt is an author at Mountain Blue Cancer Care Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	989
2	Health Sciences	1	1	21
3	Public Health	1	1	16
4	Allergy	1	1	30
5	Cell Biology	1	1	134

Jerome H. Goldschmidt

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer David R. Spigel, Thomas J. Ervin, Rodryg Ramlau, Journal of Clinical Oncology	2013	474
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial Makoto Nishio, Fabrice Barlési, Howard West, Journal of Thoracic Oncology	2020	430
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. David R. Spigel, Thomas J. Ervin, Rodryg Ramlau, Journal of Clinical Oncology Advanced NsclcFinal Efficacy ResultsOncologyClinical TherapeuticMetronomic Therapy	2011	194
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt, Lung Cancer Exploratory AnalysesBrain MetastasesMedicineMetronomic TherapyPathology	2018	169
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study David R. Gandara, Joachim von Pawel, Julien Mazières, Journal of Thoracic Oncology Advanced NsclcOncologyMedicineMetronomic TherapyPharmacotherapy	2018	156
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older Andres Forero‐Torres, Beata Holkova, Jerome H. Goldschmidt, Blood	2015	137
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, Cory Batenchuk, A. Badzio, Journal of Thoracic Oncology OncologyPd-l1 ExpressionMedicinePathologyCancer Genomics	2016	134
OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, Manuel Cobo, Rodolfo Bordoni, Journal of Thoracic Oncology OncologyMedicinePharmacotherapyOa05.07 Impower132Safety Results	2018	120
Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer Robert C. Doebele, David R. Spigel, Mustapha Tehfé, Cancer	2014	84
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase <scp>II</scp> trial Davey B. Daniel, Vladimer Kuchava, Igor Bondarenko, International Journal of Cancer	2020	78

Page 1